Saturday, October 1, 2022


Biotechnology News Magazine

Grindeks Expands Range of Generic Medicines and Activities in International Markets

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Grindeks, the leading pharmaceutical enterprise in the Baltic States, announces its goals on essential expansion of a range of generic Expandsand activities in international markets.

Grindeks believes that it has great potential to expand patients’ access to high-quality and effective medicines for treatment of important therapeutic directions – CNS diseases, cardiovascular diseases, diabetes and oncological diseases. In addition, Kalceks, a subsidiary enterprise of Grindeks, has made a convincing announcement of its presence in global competition in the hospital segment.

In recent years, the Grindeks Group has been growing rapidly and it is confident that, unlike the leaders of the global pharmaceutical market, it is able to respond quickly and flexibly to the needs and requirements of patients. The enterprise has been fulfilling drug development processes, knowledge transfer, and continuous infrastructure development, in order to expand a portfolio of the generic products.

In 2022, Grindeks plans to apply 18 generic medicines for registration. Kalceks, the subsidiary enterprise, will apply 10 medicines for registration in the hospital segment.

Production of active pharmaceutical ingredients is also very important for the Group, since it is one Grindeks competitive advantages increasing its independence from raw material manufacturers. The enterprise as of now produces 25 active pharmaceutical ingredients, and they are in great demand. 46 new active pharmaceutical ingredients are under development.

To ensure availability of the medicienes of Grindeks and Kalceks for the patients, the Group has been developing its activities around the world. Last year, Grindeks products were exported to 103 countries worldwide. Along with the already existing representative offices and subsidiaries, subsidiary enterprises shall be opened this year in the USA, Switzerland and a number of countries of the European Union.

Dr. chem. Juris Hmelnickis, Chairman of the Board of Grindeks: “There are no unattainable goals if an enterprise works confidently, putting the needs of patients at the forefront. Grindeks team has proven its ability for coordinated progress towards a common goal. We are characterized by realization that we are doing something especially important for health of mankind. It is a call to help people. In addition, we have courage, knowledge and experience. The expansion of the range of the generic medicines and of Grindeks operations will bring great benefits to the patients, as the medicines will become more accessible to them.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine